News Related to BioVersys AG

Related coverage linked through entity extraction aliases.

FDA Approves BioVersys Phase 3 Trial for Drug-Resistant Pneumonia Treatment

Mar 16, 2026

BioVersys AG received FDA approval to enroll U.S. patients in a global Phase 3 trial evaluating BV100 for hospital-acquired pneumonia caused by carbapenem-resistant Acinetobacter baumannii, with trial completion expected by end of 2027.

BioVersys Doses First Patient in Phase 2b Trial of AlpE for Tuberculosis

Mar 12, 2026

BioVersys has dosed the first patient in a Phase 2b trial evaluating alpibectir-ethionamide (AlpE) in combination with first-line TB drugs, following promising Phase 2a results published in the New England Journal of Medicine.